PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.49%
Negative EBIT growth while AVXL is at 45.10%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-15.26%
Negative operating income growth while AVXL is at 45.10%. Joel Greenblatt would press for urgent turnaround measures.
-50.43%
Negative net income growth while AVXL stands at 48.65%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-43.14%
Negative EPS growth while AVXL is at 51.92%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-43.14%
Negative diluted EPS growth while AVXL is at 51.92%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
5.01%
Share count expansion well above AVXL's 3.66%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.01%
Diluted share count expanding well above AVXL's 3.66%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-30.81%
Negative OCF growth while AVXL is at 41.41%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-30.34%
Negative FCF growth while AVXL is at 41.41%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52488.47%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-16557.44%
Negative 5Y OCF/share CAGR while AVXL is at 42.28%. Joel Greenblatt would question the firm’s operational model or cost structure.
-182.36%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-47013.60%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-7873.57%
Negative 5Y net income/share CAGR while AVXL is 81.60%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-9.65%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
20722.38%
10Y equity/share CAGR above 1.5x AVXL's 3597.11%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5960.52%
5Y equity/share CAGR above 1.5x AVXL's 240.80%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
359.30%
3Y equity/share CAGR above 1.5x AVXL's 160.52%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.39%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-49.71%
We’re deleveraging while AVXL stands at 7.02%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.16%
R&D dropping or stable vs. AVXL's 97.90%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
23.98%
We expand SG&A while AVXL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.